1) 西村恒彦:バイオメディカルイメージングの展望. 鳥塚莞爾編, クリニカルPET, 東京, 先端医療技術研究所, 1997.
2) 西村恒彦, 油谷健司, 巽 光朗・他:同時計数回路方式を用いたFDG-SPECT(Molecular Coincidence Detection)の臨床応用. 映像情報メディカル, 30, 727-732, 1998.
3) Patton, J. A. :Instrumentation for coincidence imaging with multihead scintillation cameras. Semin. Nucl. Med., 30, 239-254, 2000.
4) Martin, W. H., Delbeke, D., Patton, J. A., et al. :FDG-SPECT;Correlation with FDG-PET. J. Nucl. Med., 36, 988-995, 1995.
5) Burt, R. W., Perkins, O. W., Oppenheim, B. E., et al. :Direct comparison of fluorine-18-FDG SPECT, fluorine-18-FDG PET and rest thallium-201 SPECT for detection of myocardial viability. J. Nucl. Med., 36, 176-179, 1995.
6) Kunze, W, D., Baehre, M., Richter, E. :PET with a dual-head coincidence camera;Spatial resolution, scatter fraction, and sensitivity. J. Nucl. Med., 41, 1067-1074, 2000.
7) Yutani, K., Tatsumi, M., Shiba, E., et al. :Comparison of dual-head coincidence gamma camera FDG imaging with FDG PET in detection of breast cancer and axillary lymph node metastasis. J. Nucl. Med., 40, 1003-1008, 1999.
8) Minoshima, S., Giordani, B., Berent, S., et al.:Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann. Neurol., 42, 85-94, 1997.
9) Tillisch, J., Brunken, R., Marshall, R., et al. :Reversibility of cardiac wallmotion abnormalities predicted by positron tomography. N. Engl. J. Med., 314, 884-888, 1986.
10) Bonow, R. O., Dilsizian, V., Cuocolo, A., et al. :Identification of viable myocardium in patients with chronic coronary artery disease and left ventricular dysfunction;Comparison of thallium scintigraphy with reinjection and PET imaging with 18F-fluorodeoxyglucose. Circulation, 83, 26-37, 1991.
11) Bar-Shalom, R., Valdivia, A. Y., Blaufox, M. D. :PET imaging in oncology. Semin. Nucl. Med., 30, 150-185, 2000.
12) Conti, P. S., Lilien, D. L., Hawley, K., et al. :PET and[18F]-FDG in oncology;A clinical update. Nucl. Med. Biol., 23, 717-735, 1996.
13) Frank, A., Lefkowitz, D., Jaeger, S., et al. :Decision logic for retreatment of asymptomatic lung cancer recurrence based on positron emission tomography findings. Int. J. Radiat. Oncol. Biol. Phys., 32, 1495-1512, 1995.
14) FDG-PET検査の臨床的有用性と医療経済効果に関する全国調査報告. Radio Isotope, 49(3), V-XLIII, 2000.
15) Gambhir, S. S., Hoh. C. K., Phelps, M. E., et al. :Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma. J. Nucl. Med., 37, 1428-1436, 1996.
16) Hasegawa, S., Uehara, T., Yamaguchi, H., et al. :Validity of 18F-fluorodeoxyglucose imaging with a dual-head coincidence gamma camera for detection of myocardial viability. J. Nucl. Med., 40, 1884-1892, 1999.
17) Nowak, B., Zimny, M., Schwarz, E. R., et al. :Diagnosis of myocardial viability by dual-head coincidence gamma camera fluorine-18fluoro-deoxyglucose positron emission tomography with and without non-uniform attenuation correction. Eur. J. Nucl. Med., 27, 1501-1508, 2000.
18) Shreve, P. D., Steventon, R. S., Deters, E. C., et al. :Oncologic diagnosis with 2-[fluorine-18]fluoro-2-deoxy-D-glucose imaging;Dual-head coincidence gamma camera versus positron emission tomographic scanner. Radiology, 207, 431-437, 1998.
19) Zimny, M., Kaiser, H. J., Cremerius, U., et al. :Dual-head gamma camera 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography in oncological patients;Effects of non-uniform attenuation correction on lesion detection. Eur. J. Nucl. Med., 26, 818-823, 1999.
20) Tatsumi, M., Yutani, K., Watanabe, Y., et al. :Feasibility of fluorodeoxyglucose dual-head gamma camera coincidence imaging in the evaluation of Iung cancer;Comparison with FDG PET. J. Nucl. Med., 40, 566-573, 1999.
21) Tatsumi, M., Kitayama, H., Sugahara, H., et al. :Whole-body hybrid positoron emission tomography with 2-18F-Fluoro-2-deoxy-D-glucose in the staging of non-Hodgleis lymphoma. J. Nucl. Med., 42, 601-608, 2001.